Evidence map›Paper›PMID 41176313›Full record

ArticleJournal for immunotherapy of cancer2025

Systemic immunosuppression from ultraviolet radiation exposure inhibits cancer immunotherapy.

Pedro Durao, Timothy Budden, Karthik Mallela, Martha Gutteridge, Isabella Mataloni, Shilpa Gurung, Mirco Mastrangelo, Luke Roberts, Antonia Banyard, Garry Ashton and 4 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pedro DuraoSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Timothy BuddenSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Karthik MallelaSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Martha GutteridgeSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Isabella MataloniSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Shilpa GurungSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Mirco MastrangeloSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-2232-7090
Luke RobertsDivision of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, UK.
Antonia BanyardCancer Research UK Flow Cytometry Facility, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK.
Garry AshtonCancer Research UK Histology Facility, Cancer Research UK Manchester Institute; The University of Manchester, Manchester, UK.
Graham M LordCentre for Gene Therapy and Regenerative Medicine, School of Basic and Medical Biosciences; Faculty of Life Sciences and Medicine, King's College London, London, UK.
Adam HurlstoneDivision of Infection Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0001-5260-9457
Sara ValpioneThe Christie NHS Foundation Trust, Manchester, UK.
Amaya VirosSkin Cancer and Ageing Lab, Cancer Research UK Manchester Institute; The Oglesby Cancer Research Building, The University of Manchester, Manchester, UK amaya.viros@cruk.manchester.ac.uk.ORCID http://orcid.org/0000-0001-5177-5015

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundUltraviolet radiation (UVR) affects local cutaneous and systemic immunity acutely. The wavelength, pattern and intensity of UVR exposure, individual skin phototype and immune state of individuals modulate the impact of UVR systemically. Local cutaneous immunity after UVR leads to immunosuppression that impacts melanoma. However, the effects of systemic UVR-induced changes on solid cancer therapy are not known.

methodsWe investigated the impact of repeated UVR exposure on systemic immunity and immune checkpoint blockade (ICB) tumor responses in colorectal cancer and melanoma mouse models.

resultsAnimals exposed to chronic UVR exhibit decreased ICB response, which is mediated by systemic factors. Repeated UVR exposure expanded systemic lymphocyte populations and contracted total systemic myeloid cells. Specifically, UVR expanded peripheral blood CD4 DISCUSSION: Our data indicate that patients with melanoma and other cancers on immunotherapy should avoid repeated sun exposure.

Indexed as

Immune ToleranceImmunosuppression TherapyImmunotherapyMelanomaSkin NeoplasmsUltraviolet RaysAnimalsFemaleHumansMaleMiceT-Lymphocytes, RegulatoryColorectal CancerImmune Checkpoint InhibitorSkin CancerT regulatory cell - Treg

Identifiers

PMID41176313
PMCPMC12581074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.